US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Spermosens calls SEK 4.85 million under previously announced Capital Facility

Spermosens AB (publ) ("Spermosens" or the "Company") hereby announces that the Board of Directors has today resolved to call capital under the capital facility of SEK 4.85 million that was announced on 7 May 2026 and subsequently approved by the Annual General Meeting on 18 June 2026. In accordance with the terms of the Capital Facility, the full available amount of SEK 4.85 million has been called. The capital will be contributed to the Company through the issuance of units to the investors participating in the Capital Facility.Summary of key terms · The total amount called under the

Spermosens provides an update on the Generation 3 clinical study

Spermosens AB (publ) (“Spermosens” or the “Company”) provides an update on the ongoing clinical study of JUNO-Checked Generation 3 at the Reproductive Medicine Centre (RMC) in Malmö. Recruitment is progressing ahead of plan, with 43 patients included to date. The Company’s ambition remains, as previously communicated, to complete the study during 2026.The Generation 3 clinical study is a central element in the Company’s strategy to demonstrate the clinical value of JUNO-Checked and to pursue commercialization through partnerships. The study evaluates JUNO-Checked, which measures the sperm

Bulletin from Annual General Meeting in Spermosens AB (publ)

Today, June 18, 2026, the Annual General Meeting was held. Below is a summary of the decisions that were made. All decisions were made with the required majority.   Adoption of the income statement and balance sheet and discharge from liability The AGM resolved to adopt the income statement and balance sheet. The AGM further resolved to discharge the Board members and the CEO from liability.   Allocation of results The AGM resolved to dispose of the company’s results in accordance with the Board’s proposal in the annual report. The AGM further resolved that no dividend be

Spermosens publishes annual report for the financial year 2025

Spermosens hereby announces that the annual report for 2025 is now available for download on the company's website, www.spermosens.com. The annual report is also attached as a PDF to this press release. Please note that this version is an English translation of the official Swedish annual report (Årsredovisning) and has not been audited. As previously announced, the Annual General Meeting will be held on 18 June 2026. In 2025, Spermosens successfully completed its clinical study at the Reproductive Medicine Center (RMC) in Malmö ahead of schedule. The study demonstrated a

Spermosens publicerar årsredovisning för räkenskapsåret 2025

Spermosens meddelar härmed att årsredovisningen för 2025 nu finns tillgänglig för nedladdning på bolagets webbplats, www.spermosens.com. Årsredovisningen bifogas även som PDF till detta pressmeddelande. Som tidigare meddelats hålls årsstämman den 18 juni 2026. Under 2025 slutförde Spermosens framgångsrikt sin kliniska studie vid Reproduktionsmedicinskt centrum (RMC) i Malmö, tidigare än planerat. Studien visade en statistiskt signifikant korrelation mellan spermiernas bindningsförmåga och fertiliseringsgrad vid IVF, vilket bekräftade det diagnostiska värdet av JUNO-Checked. Bolagets

NOTICE OF ANNUAL GENERAL MEETING 2026 IN SPERMOSENS AB (publ)

The shareholders of Spermosens AB (publ), reg. no. 559179-0380, are hereby invited to attend the Annual General Meeting on Thursday, 18 June 2026 at 10:00 a.m. at Medicon Village (The Spark), Scheeletorget 1, Lund, Sweden.   Right to participate and notice of participation Shareholders wishing to participate in the Annual General Meeting must: · be registered as shareholders in the share register maintained by Euroclear Sweden AB on Wednesday, 10 June 2026; and · notify the company of their intention to participate no later than Friday, 12 June 2026, in writing to

KALLELSE TILL ÅRSSTÄMMA 2026 I SPERMOSENS AB (publ)

Aktieägarna i Spermosens AB, org. nr. 559179-0380, kallas härmed till årsstämma torsdagen den 18 juni 2026 kl. 10.00 på Medicon Village (The Spark), Scheeletorget 1, i Lund.   Rätt att delta och anmälan Aktieägare som önskar delta i bolagsstämman ska · vara upptagen som aktieägare i den av Euroclear Sweden AB förda aktieboken onsdagen den 10 juni 2026, och · anmäla sig till bolaget senast fredagen den 12 juni 2026, skriftligen till Spermosens AB, Medicon Village, Scheeletorget 1, 223 81 Lund (märk brevet ”Årsstämma 2026”) eller per e-post till adressen info@spermosens.com.

Spermosens AB (publ) to Host Live Q&A Webcast on 19 May 2026

Spermosens AB (publ) ("Spermosens" or the "Company") today announces that it will host a live Q&A webcast on Tuesday, 19 May 2026, at 12:00 CET. CEO Tore Duvold will address questions regarding the Company's recent announcementsThe session is organised as a dedicated Q&A to provide shareholders and other stakeholders with the opportunity to engage directly with the Company's CEO. The webcast follows the publication of the Company's Q1 2026 report and forms part of Spermosens' commitment to regular investor engagement, with Q&A sessions typically held approximately one week after the

Spermosens secures SEK 4.85 million capital facility to support development and commercialization

Spermosens AB (publ) (“Spermosens” or the “Company”) has entered into agreements with a group of existing shareholders, including Chairman of the Board Ulrik Spork and CEO Tore Duvold, regarding a capital facility of SEK 4.85 million (the “Capital Facility”), to be utilized in a single drawdown. The Capital Facility entails participation in a directed issue of units (shares and warrants) upon a call of capital. The Capital Facility is intended to provide financial flexibility and support the Company’s continued development and commercialization of JUNO-Checked. The Capital Facility is subject

Spermosens AB (publ) INTERIM REPORT JANUARY – MARCH 2026

In the first quarter of 2026, Spermosens completed the third generation of the JUNO-Checked diagnostic system, initiated a new clinical validation study building on successful clinical results from 2025, and advanced partnership discussions in the US and internationally.1 JANUARY – 31 MARCH 2026 SIGNIFICANT EVENTS DURING THE INTERIM PERIOD  16 January, 2026 Spermosens and Sapyen sign Memorandum of Understanding to advance male                                                                                fertility diagnostics 26 January, 2026 Spermosens and RSI sign Memorandum of

Spermosens reports JUNO-Checked Generation 3 clinical validation study on track

Spermosens AB ("Spermosens" or the "Company") today reports that the clinical validation study of the JUNO-Checked Generation 3 system at the Reproductive Medicine Center (RMC) in Malmö has started and is progressing according to plan. Seven patients have been successfully tested to date. The study started in April 2026, in line with the previously communicated timeline.As announced recently, the Company completed development of the Generation 3 system and planned to initiate patient recruitment at the RMC in Malmö. The study is now underway, and the first weeks confirm that patient

Spermosens completes development of JUNO-Checked Generation 3 and initiates clinical validation study

Spermosens AB (“Spermosens” or the “Company”) announces that development of the JUNO-Checked Generation 3 system is now complete.  This innovative sensor system meets the performance standards necessary for a commercially viable product. The Company is preparing to initiate patient recruitment for a clinical validation study at the Reproductive Medicine Center (RMC) in Malmö. This represents a major milestone in the strategic plan to bring improved fertility diagnostics to the market through commercial partnerships.Significant improvements of JUNO-Checked Generation 3 The development of

Spermosens AB (publ) Issues Final Reminder for Tomorrow’s Live Q&A Webcast

Spermosens AB (publ) (“Spermosens”) provides a final reminder for its live digital Q&A webcast scheduled for tomorrow, Thursday, 26 March 2026, at 12:00 CET.The session is a dedicated platform for CEO Tore Duvold to address questions regarding the Company’s recent technical milestones, clinical evidence, and the transition toward commercial partnerships. As we finalize Generation 3.0 and execute our partner-led strategy, we remain focused on replacing estimation with evidence in the global fertility diagnostics market. Webcast Details: · Date: Thursday, 26 March 2026. · Time: 12:

Spermosens AB (publ) to Host Live Q&A Webcast Following Recent Progress

Spermosens AB (publ) (“Spermosens” or the “Company”) today announces that it will host a live Q&A webcast on Thursday, 26 March 2026, at 12:00 CET. CEO Tore Duvold will address questions regarding the Company’s recent announcements and ongoing technical, clinical and commercial developments.The session is organized as a dedicated Q&A to provide shareholders and other stakeholders with the opportunity to engage directly with the Company. Following the successful clinical validation of the JUNO-Checked system and the Company’s transition toward commercial partnerships, this webcast serves as

Spermosens AB (publ)YEAR-END REPORT JANUARY – DECEMBER 2025 - CORRECTED

Correction: The Year-End Report referred to in the press release published earlier today was inadvertently omitted. The complete report is now attached. We have reached important results staying uncompromisingly focused on what matters and refusing to be distracted. By replacing estimation with evidence, we are turning a great invention into a great product.   1 JANUARY – 31 DECEMBER 2025 SIGNIFICANT EVENTS DURING THE QUARTER  22-10-2025 - Spermosens receives patent approval in Canada 03-11-2025 - Spermosens receives patent approval in Mexico 04-11-2025 - Spermosens

Spermosens AB (publ)YEAR-END REPORT JANUARY – DECEMBER 2025

We have reached important results staying uncompromisingly focused on what matters and refusing to be distracted. By replacing estimation with evidence, we are turning a great invention into a great product.   1 JANUARY – 31 DECEMBER 2025 SIGNIFICANT EVENTS DURING THE QUARTER  22-10-2025 - Spermosens receives patent approval in Canada 03-11-2025 - Spermosens receives patent approval in Mexico 04-11-2025 - Spermosens receives patent approval in Israel 18-11-2025 - Spermosens receives patent approval in China 08-12-2025 - Spermosens announces outcome of exercise of

Spermosens and RSI sign Memorandum of Understanding to advance male fertility diagnostics in the US

Spermosens AB has entered into a Memorandum of Understanding (MoU) with RSI Technology Group (RSI), a US-based medical device company developing innovative solutions for sperm collection and preparation. The MoU reflects the parties’ intention to explore a potential collaboration aimed at evaluating a combined approach for introducing Spermosens’ diagnostic method, JUNO‑Checked, into the United States fertility market.Male fertility diagnostics continues to face challenges related to sample quality, standardization, and clinically relevant insight into male fertilization potential. RSI has

Spermosens and Sapyen sign Memorandum of Understanding to advance male fertility diagnostics

Spermosens AB has entered into a Memorandum of Understanding (MoU) with Sapyen, a global male fertility diagnostics company with operations across the US, Europe, UK and Australia. The MoU reflects the parties’ intention to evaluate a potential collaboration with the aim of establishing a partner-led commercialization model for Spermosens’ diagnostic method, JUNO-Checked.Male fertility diagnostics is undergoing a structural shift, driven by increasing demand for patient-friendly access combined with clinical-grade data. Sapyen has established a model that enables home-based sample

Spermosens shares progress and plans for partner-driven commercialization

Spermosens AB (“Spermosens” or the “Company”) presents an update on recent progress and the next steps in its partner-driven commercialization strategy for JUNO-Checked. The Company completed a successful clinical study in June 2025, confirming the diagnostic value of JUNO-Checked and continues to build a strong foundation for a partner-led market introduction. Development of Generation 3, the intended commercial version, is progressing and dialogues with potential partners in Europe, the United States, Japan and Australia are advancing. Central to the Company’s go-to-market strategy is the

Spermosens announces outcome of exercise of warrants series TO 4

Spermosens AB (publ) ("Spermosens" or the "Company") today announces the outcome of the TO 4 series of warrants, issued in connection with the rights issue announced on 20 February 2024. The subscription price for the TO 4 warrants was set at SEK 0.15, determined prior to the issuance of new shares in the rights issue completed in November 2024. The warrants were available for subscription from 17 November 2025 to 1 December 2025. As the subscription price exceeded the prevailing market price, no subscriptions were received. Consequently, the anticipated increase in share capital and

Spermosens announces last day of trading for warrants of series TO 4

Spermosens AB ("Spermosens" or "the Company") announces that the last day of trading for the warrants of series TO 4 on Spotlight Stock Market is 27 November 2025.The warrants of series TO 4 were issued in connection with the rights issue announced on 20 February 2024, with a subscription period that ended on 17 April 2024. Each warrant entitles the holder to subscribe for one (1) new share in Spermosens at a subscription price of SEK 0.15. The exercise period for the warrants runs from 17 November 2025 to 1 December 2025. The subscription price of SEK 0.15 was determined before the

Spermosens receives patent approval in China

Spermosens AB (“Spermosens” or the “Company”) today announces that the patent “Biosensor for Male Infertility” (ZL 2019800555646) has been granted in China. The patent covers the Company’s method for measuring sperm binding to the egg receptor JUNO, a critical biological interaction during fertilization that no existing standard test can evaluate.The patent granted in China further strengthens Spermosens’ global intellectual property portfolio, which already includes granted patents in key markets including Europe, the United States of America, Japan, South Korea, Australia, South Africa,

Spermosens AB (publ) INTERIM REPORT JANUARY - SEPTEMBER 2025

After demonstrating the diagnostic value of JUNO-Checked earlier this year, we have now taken the next steps preparing for the market.JANUARY 1st – SEPTEMBER 30st 2025   SIGNIFICANT EVENTS DURING THE QUARTER 07-08-2025 Spermosens provides status update following successful clinical study SIGNIFICANT EVENTS AFTER THE END OF THE INTERIM PERIOD 04-11-2025 Spermosens receives patent approval in Israel 03-11-2025 Spermosens receives patent approval in Mexico 22-10-2025 Spermosens receives patent approval in Canada     FINANCIAL INFORMATION

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe